Fernando Barata

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer

Glen J. Weiss, Rafael Rosell, Frank V. Fossella et al. · Annals of Oncology · 2007 · 75 citations · Full text

Medicine, Bronchial Neoplasm, Pharmacotherapy +7

Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

Alberto Chiappori, Gerold Bepler, Fabrice Barlési et al. · Journal of Thoracic Oncology · 2010 · 40 citations · Full text

Oncology, Phase Ii, Medicine +8

: P2-235: Optimal duration of chemotherapy in non-small-cell lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs 6 cycles of carboplatin and gemcitabine

Fernando Barata, Bárbara Parente, Encarnação Teixeira et al. · Journal of Thoracic Oncology · 2007 · 30 citations · Full text

Oncology, Optimal Duration, Medicine +10

Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC)

Ana Figueiredo, Maria Amélia Almeida, Teresa Almodôvar et al. · Pulmonology · 2019 · 27 citations · Full text